ATE275203T1 - Unsterbliche menschliche zellinien, die exogenes cytochrom p-450 gen enthalten - Google Patents

Unsterbliche menschliche zellinien, die exogenes cytochrom p-450 gen enthalten

Info

Publication number
ATE275203T1
ATE275203T1 AT94917408T AT94917408T ATE275203T1 AT E275203 T1 ATE275203 T1 AT E275203T1 AT 94917408 T AT94917408 T AT 94917408T AT 94917408 T AT94917408 T AT 94917408T AT E275203 T1 ATE275203 T1 AT E275203T1
Authority
AT
Austria
Prior art keywords
cell lines
cytochrome
gene
human cell
lines containing
Prior art date
Application number
AT94917408T
Other languages
English (en)
Inventor
Curtis C Harris
Harry V Gelboin
Frank J Gonzalez
Katharine C Mace
Andrea M A Pfeifer
Original Assignee
Us Gov Health & Human Serv
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Nestec Sa filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE275203T1 publication Critical patent/ATE275203T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT94917408T 1993-05-19 1994-05-17 Unsterbliche menschliche zellinien, die exogenes cytochrom p-450 gen enthalten ATE275203T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/065,201 US5506131A (en) 1987-06-05 1993-05-19 Immortalized human cell lines containing exogenous cytochrome P450 genes
PCT/US1994/005472 WO1994026905A1 (en) 1993-05-19 1994-05-17 Immortalized human cell lines containing exogenous cytochrome p450 genes

Publications (1)

Publication Number Publication Date
ATE275203T1 true ATE275203T1 (de) 2004-09-15

Family

ID=22061021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917408T ATE275203T1 (de) 1993-05-19 1994-05-17 Unsterbliche menschliche zellinien, die exogenes cytochrom p-450 gen enthalten

Country Status (9)

Country Link
US (2) US5506131A (de)
EP (1) EP0700442B1 (de)
AT (1) ATE275203T1 (de)
AU (1) AU697896B2 (de)
CA (1) CA2163233C (de)
DE (1) DE69433977T2 (de)
DK (1) DK0700442T3 (de)
ES (1) ES2229219T3 (de)
WO (1) WO1994026905A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665589A (en) * 1988-12-14 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Human liver epithelial cell lines
CA2128399A1 (en) * 1993-07-20 1995-01-21 Koji Hayashi Method for safety evaluation of chemical compound using recombinant yeast expressing human cytochrome p450
US6372073B1 (en) * 1999-08-11 2002-04-16 Southpac Trust International Inc. Process for producing holographic material
US5869243A (en) * 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
US5763180A (en) * 1996-08-14 1998-06-09 Viratest Carcinogen Monitoring Ltd. In vitro assay for carcinogens using phenotypic transformation of human cells
US6432639B1 (en) * 1997-09-10 2002-08-13 Dna Sciences Laboratories, Inc. Isolated CYP3A4 nucleic acid molecules and detection methods
AU1287799A (en) * 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
ATE341620T1 (de) * 1998-04-28 2006-10-15 Takeda Pharmaceutical Neue, immortalisierte leber-zelllinie humanen ursprungs
AU4188599A (en) * 1998-05-15 1999-12-06 Geron Corporation Method and apparatus for detecting hazardous agents
US6929912B2 (en) * 1998-08-31 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for evaluating the ability to metabolize pharmaceuticals
AU4143200A (en) 1999-04-27 2000-11-10 Masayoshi Nanba Human cell line showing stable expression of cytochromes p450
AU779900B2 (en) 1999-07-22 2005-02-17 Organogenesis Inc. In vivo induction for enhanced function of isolated hepatocytes
DK1290444T3 (da) 2000-06-14 2010-01-18 Vistagen Inc Toxicitetstypisering under anvendelse af lever-stamceller
US7015036B2 (en) * 2000-09-25 2006-03-21 The United States Of America As Represented By The Secretary Of The Army Human liver cell line
US7781186B2 (en) * 2000-09-25 2010-08-24 The United States Of America As Represented By The Secretary Of The Army Screening methods using normal human liver cell line
US7041501B2 (en) * 2001-10-31 2006-05-09 Bristol-Myers Squibb Company Methods of screening for toxicity of test compounds
WO2003060061A1 (en) * 2001-12-21 2003-07-24 Organogenesis Inc. Chamber with adjustable volume for cell culture and organ assist
EP1490520A4 (de) * 2002-03-12 2006-06-07 Surface Logix Inc Testvorrichtung, die die absorption, den stoffwechsel, die permeabiltät und/oder toxizität einer kandidatenverbindung analysiert
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675002A (en) * 1985-12-02 1987-06-23 Viles Joseph M Liver assist device employing transformed cell lines
US4816395A (en) * 1985-12-19 1989-03-28 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
US5164313A (en) * 1987-06-05 1992-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant vaccinia virus encoding cytochromes P-450
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
US5356806A (en) * 1987-06-05 1994-10-18 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human cell lines containing exogenous cytochrome P450
JP3519080B2 (ja) * 1990-10-15 2004-04-12 ジェンテスト・コーポレーション 前発癌物質活性化酵素をコードする５つのｃＤＮＡを安定して発現するヒト細胞株

Also Published As

Publication number Publication date
AU697896B2 (en) 1998-10-22
US5660986A (en) 1997-08-26
AU6914594A (en) 1994-12-12
DE69433977D1 (de) 2004-10-07
EP0700442B1 (de) 2004-09-01
WO1994026905A1 (en) 1994-11-24
EP0700442A1 (de) 1996-03-13
CA2163233A1 (en) 1994-11-24
ES2229219T3 (es) 2005-04-16
CA2163233C (en) 2007-01-09
DK0700442T3 (da) 2005-01-10
DE69433977T2 (de) 2005-09-01
US5506131A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
ATE254661T1 (de) Exogene cytochrom p450 gene enthaltende immortalisierte menschliche zelllinien
DE69433977D1 (de) Unsterbliche menschliche zellinien, die exogenes cytochrom p-450 gen enthalten
Møller et al. CRISPR-C: circularization of genes and chromosome by CRISPR in human cells
Lacroix Persistent use of “false” cell lines
Perrem et al. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids
AU6188599A (en) Constructing and screening a dna library of interest in filamentous fungal cells
ATE498011T1 (de) Modifizierte embryonale stammzellen und embryonales stammzellspezifisches gen
WO1998030883A3 (en) Analysis of genetic polymorphisms and gene copy number
DE69939056D1 (de) Vektoren für genmutagenese und genentdeckung
Brüsehafer et al. The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency
Ham et al. Condensin mutations and abnormal chromosomal structures in pyothorax‐associated lymphoma
DE59712319D1 (de) Genfallen-konstrukt zur identifizierung und isolierung von genen
WO1995023855A3 (en) Genes and genetic elements associated with control of neoplastic transformation in mammalian cells
WO2003035834A3 (en) Compositions and methods for making mutations in cell lines and animals
MXPA03004777A (es) Metodo para mapeo de muy alta resolucion de genes y determinacion de redes geneticas entre genes con rasgos fenotipicos subyacentes.
Hisaoka et al. Inflammatory myofibroblastic tumor with predominant anaplastic lymphoma kinase‐positive cells lacking a myofibroblastic phenotype
WO2002008451A3 (en) Assay for screening compounds for inducing drug metabolizing enzymes
AU2002215754A1 (en) Compositions, methods and kits for identifying protein-protein interaction disrupting agents
AU4853997A (en) Immortalized human corneal epithelial cell line
Zomer et al. Mouse Sertoli cells isolation by lineage tracing and sorting
Tonge et al. Prepatterning in the stem cell compartment
AU2311697A (en) Immuno-magnetic cell separation used in identification of genes associated with site-preferenced cancer methastasis formation
Busley et al. Generation of a genetically-modified induced pluripotent stem cell line harboring an oncogenic gene variant KRAS p. G12V
Harris et al. Immortalized human cell lines containing exogenous cytochrome P450
Mori et al. Loss of DAXX induces alternative lengthening of telomeres (ALT)-associated hallmarks in prostate cancer cells in a context-specific manner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0700442

Country of ref document: EP